Research & Commercialization
尽管EBI在俄亥俄大学教职员工中所占比例不到1%，但截至2016年底，EBI技术的商业化产生了约1亿美元的收入，占俄亥俄大学版税收入的95%以上。
该所的研究延续了基础研究的传统，并结合了对商业化的严谨、实际的关注，以便将发现应用于人类健康。 我们在分子和细胞生物学，遗传学，蛋白质组学和激素调节方面的研究解决了以下领域未满足的治疗需求：
- Growth disorders
- Diabetes and obesity
- Autoimmune diseases
- Inflammation
- Neurodegeneration
- Aging
- Infectious diseases
- Cancer
These research themes are being pursued for the development of biomedical diagnostics and therapeutics both individually at EBI and in collaboration with other academic and corporate partners. Over the past three decades, this interdisciplinary and entrepreneurial approach has produced:
- 30 U.S. patents
- 1 U.S. patent applications pending
- 25 active invention disclosures
This science continues our best tradition and mission of enhancing not only human health globally but also the economic health of the southeastern Ohio region.
Funding Sources
The Edison Biotechnology Institute is supported by the Ohio Department of Development, the Goll-Ohio Eminent Scholar Endowment, Ohio University, federal agencies, foundations, corporate sponsored research agreements, royalty revenues, and gifts.